Regeneron Pharmaceuticals is conducting a Phase 3 clinical trial titled ‘A Phase 3, Open-Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20x Anti-CD3 Bispecific Antibody, Combined With Chemotherapy Versus Rituximab Combined With Chemotherapy in Previously Untreated Participants With Follicular Lymphoma (OLYMPIA-2)’. The study aims to evaluate the safety, tolerability, and efficacy of odronextamab combined with chemotherapy compared to the standard treatment of rituximab with chemotherapy in adults with follicular lymphoma.

The intervention being tested is odronextamab, an experimental bispecific antibody designed to target CD20 and CD3 proteins, administered with chemotherapy drugs like cyclophosphamide, doxorubicin, vincristine, and prednisone. The goal is to determine if this combination is more effective than the current standard treatment.

This interventional study is randomized with a parallel assignment model and no masking, focusing on treatment as its primary purpose. It includes three parts, with Part 1 focusing on dose optimization and Part 2 comparing the efficacy of odronextamab with the standard treatment.

The study began on November 14, 2023, with primary completion expected by July 29, 2025. These dates are crucial for tracking the progress and potential early results of the trial, which could influence market dynamics.

The outcome of this study could significantly impact Regeneron’s stock performance and investor sentiment, especially if odronextamab proves to be a superior treatment option. This could also affect competitors in the oncology space, as new, effective treatments often shift market positions.